SEC Comment Letter 0000000000-23-012952 to Panbela Therapeutics, Inc. (PBLA) (CIK 0001029125)
Panbela Therapeutics, Inc. (PBLA) (CIK 0001029125)
Date: Nov. 28, 2023 · CIK: 0001029125 · Accession: 0000000000-23-012952
AI Filing Summary & Sentiment
File numbers found in text: 333-275733
Letter
United States securities and exchange commission logo November 28, 2023 Jennifer K. Simpson Chief Executive Officer Panbela Therapeutics, Inc. 712 Vista Blvd, Suite 305 Waconia, MN 55387 Re:Panbela Therapeutics, Inc. Registration Statement on Form S-1 Filed November 22, 2023 File No. 333-275733 Dear Jennifer K. Simpson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Joshua L. Colburn, Esq.
Show Raw Text
United States securities and exchange commission logo
November 28, 2023
Jennifer K. Simpson
Chief Executive Officer
Panbela Therapeutics, Inc.
712 Vista Blvd, Suite 305
Waconia, MN 55387
Re:Panbela Therapeutics, Inc.
Registration Statement on Form S-1
Filed November 22, 2023
File No. 333-275733
Dear Jennifer K. Simpson:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Joshua L. Colburn, Esq.